Humacyte Q2 2023 Earnings Report $4.65 +0.01 (+0.22%) (As of 05:45 PM ET) Earnings HistoryForecast Humacyte EPS ResultsActual EPS-$0.22Consensus EPS -$0.22Beat/MissMet ExpectationsOne Year Ago EPS-$0.19Humacyte Revenue ResultsActual RevenueN/AExpected Revenue$0.10 millionBeat/MissN/AYoY Revenue GrowthN/AHumacyte Announcement DetailsQuarterQ2 2023Date8/14/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseSEC FilingHUMA Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Humacyte Earnings HeadlinesHumacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)December 23 at 5:44 PM | seekingalpha.comHumacyte price target raised to $17 from $15 at BenchmarkDecember 23 at 12:41 PM | markets.businessinsider.comNo one’s talking about these Trump tradesAs you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”December 23, 2024 | Insiders Exposed (Ad)HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law FirmDecember 23 at 10:27 AM | prnewswire.comInvestors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to ...December 23 at 6:07 AM | gurufocus.comInvestors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMADecember 23 at 5:45 AM | prnewswire.comSee More Humacyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Humacyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Humacyte and other key companies, straight to your email. Email Address About HumacyteHumacyte (NASDAQ:HUMA) engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.View Humacyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
